Summary: In this podcast, experts discuss how to overcome obstacles that span from discovery to launch of orphan drugs as well as discuss the needs of patients and drug developers in orphan biologics development.

Summary: A scalable, CGMP-ready process for viral vector manufacturing that reduces the current 18-20-month development timeline for drug product in half.

Summary: Our iPSC banks utilize specialized reprogramming technology to transform commercial-use donor consented, clinically approved, cord blood collections into HLA-homozygous lines that are immune compatible with a wide population.

Summary: The field’s top experts weigh in on the technologies they are working on, including self-amplifying RNA, computer-designed nanoparticles, expanding mRNA processes and...

Summary: Securing the supply of this critical raw material will help biotech and pharma companies throughout the drug development lifecycle of their advanced therapies.

Summary: In this webinar, experts discuss the formulation development challenges, considerations, and potential solutions associated with...

Summary: In this podcast, we will discuss how Catalent is working to simplify the supply chain, develop processes scalable for late-stage and commercial needs, and accelerate timelines for production of clinical materials.

Summary: During this session, we review progress in several areas of advanced development and their impact on readiness for large scale manufacturing.

Summary: During this panel discussion, executives share how their companies adapted to the challenges and what lessons they will take forward to ensure...

Summary: In December 2021, John Chiminski was featured on the expert panel of STAT’s "A Look Ahead at Biotech in 2022" event, which focused on the ongoing battle against the SARS-CoV-2 virus and explored what might be in store for the biotech industry in the years to come.